Edgewise Therapeutics (EWTX) Amortizatization of Intangibles (2022 - 2026)
Edgewise Therapeutics (EWTX) reported Amortizatization of Intangibles of $1.0 million for Q1 2026, up 2370.73% on a YoY basis from $41000.0 in Q1 2025, and down 31.69% sequentially from $1.5 million in Q4 2025.
Edgewise Therapeutics (EWTX) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Edgewise Therapeutics (EWTX) has 5 years of Amortizatization of Intangibles data on file, last reported at $1.0 million in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles rose 2370.73% year-over-year to $1.0 million; the trailing twelve-month figure through Mar 2026 stood at $8.6 million (up 399.07% YoY), and the FY2025 full-year result was $7.7 million, up 3368.33% from the prior year.
- Amortizatization of Intangibles fell to $1.0 million in Q1 2026, from $1.5 million in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $9.4 million in Q4 2023 to a low of -$6.5 million in Q3 2024.
- A 5-year average of $1.1 million and a median of $771000.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles slumped 13712.5% in 2024 and soared 2751.92% in 2025, its largest moves.
- Tracing EWTX's Amortizatization of Intangibles over 5 years: stood at $377000.0 in 2022, then surged by 2389.66% to $9.4 million in 2023, then sank by 99.45% to $52000.0 in 2024, then soared by 2751.92% to $1.5 million in 2025, then plunged by 31.69% to $1.0 million in 2026.
- Business Quant data shows EWTX's Amortizatization of Intangibles at $1.0 million in Q1 2026, $1.5 million in Q4 2025, and $2.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Edgewise Therapeutics | 4.46 Bn | 4.46 Bn | - | 1.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.01 Mn |
| Mar 31, 2026 | 1.01 Mn |
| Dec 31, 2025 | 1.48 Mn |
| Dec 31, 2025 | 1.48 Mn |
| Sep 30, 2025 | 2.06 Mn |
| Sep 30, 2025 | 2.06 Mn |
| Jun 30, 2025 | 4.09 Mn |
| Jun 30, 2025 | 4.09 Mn |
| Mar 31, 2025 | 41,000.00 |
| Mar 31, 2025 | 41,000.00 |
| Dec 31, 2024 | 52,000.00 |
| Dec 31, 2024 | 52,000.00 |
| Sep 30, 2024 | -6.53 Mn |
| Sep 30, 2024 | -6.53 Mn |
| Jun 30, 2024 | 3.55 Mn |
| Jun 30, 2024 | 3.55 Mn |
| Mar 31, 2024 | 3.15 Mn |
| Mar 31, 2024 | 3.15 Mn |
| Dec 31, 2023 | 9.39 Mn |
| Dec 31, 2023 | 9.39 Mn |